Christiana Care, Strata Precision Oncology Offering Next-Generation Tumor Profiling at No Cost
The Christiana Care Health System is partnering with Strata Precision Oncology Network to offer next-generation tumor profiling at no cost to patients with advanced or rare cancers.
Eligible patients will be matched to the best available clinical trials or most innovative therapy, beginning on February 1, 2018.
“This partnership with Strata will give our patients the opportunity to participate in precision medicine clinical trials without leaving the state of Delaware,” said Nicholas J Petrelli, MD, Bank of America endowed medical director, Christiana Care’s Helen F Graham Cancer Center & Research Institute, in a press release (January 4, 2018). “Tumor profiling is becoming the state-of-the-art, and by collaborating with the unique strengths of Strata, the Graham Cancer Center will continue to stay on the cutting edge of cancer treatment and prevention.”
Many patients treated at regional or community cancer centers do not receive the often-costly, routine tumor genome sequencing until all standard treatments have been used. As a result, patients with advanced cancer remain unaware of the molecular characteristics of their disease and pharmaceutical companies have difficulty finding patients for trials of new precision drugs that target specific DNA mutations.
“We are excited to partner with Strata to offer our patients with advanced cancer the opportunity to more fully characterize their tumors with the latest technology in molecular tumor profiling to better understand the molecular biology of their cancers,” said lung cancer specialist Greg Masters, MD, principal investigator, National Cancer Institute Community Oncology Research Program, Graham Cancer Center (January 4, 2018). “We believe this will ultimately lead to more effective treatments and research trial participation targeting the unique genetic abnormalities of each patient’s cancer with precision. And this will be done without added expense for our patients or their insurance company.”
The Strata trial will be available at 50 hospitals in the Strata network, covering 75,000 analytic cancer cases per year. Among the other participating institutions are Kaiser Permanente-Northern California, Kettering Health Network, and the University of Texas Health Sciences Center at Houston. Strata plans to provide genome sequencing to 100,000 patients within the next 3 years.—Zachary Bessette